Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
Authors: Elisabetta Patorno, Phyo T. Htoo, Brendan M. Everett, Seoyoung C. Kim
Journal: Annals of Internal Medicine (2022)

LettersJanuary 2022Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseElisabetta Patorno, MD, DrPH, Phyo T. Htoo, MD, PhD, Brendan M. Everett, MD, MPH*, Seoyoung C. Kim, MD, ScD*Elisabetta Patorno, MD, DrPHBrigham and Women's Hospital and Harvard Medical School, Boston, MassachusettsSearch for more papers by this author, Phyo T. Htoo, MD, PhDBrigham and Women's Hospital and Harvard Medical School, Boston, MassachusettsSearch for more papers by this author, Brendan M. Everett, MD, MPH*Brigham and Women's Hospital and Harvard Medical School, Boston, MassachusettsSearch for more papers by this author, Seoyoung C. Kim, MD, ScD*Brigham and Women's Hospital and Harvard Medical School, Boston, MassachusettsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L21-0708 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree with Dr. Bepo and colleagues that not all placebo-controlled cardiovascular outcome trials showed consistent cardiovascular benefits in patients with T2D across individual GLP-1 RAs and SGLT2 inhibitors. For example, among SGLT2 inhibitors, dapagliflozin and ertugliflozin did not show a reduction in the risk for major adverse cardiovascular events (1, 2). Similarly, among GLP-1 RAs, lixisenatide and exenatide did not reduce the risk for these events (3, 4); however, exenatide did reduce the risk for all-cause mortality compared with placebo (4).Whether this effect heterogeneity among individual GLP-1 RAs and SGLT2 inhibitors is due to structural differences ...References1. Wiviott SD, Raz I, Bonaca MP, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-57. [PMID: 30415602] doi:10.1056/NEJMoa1812389 CrossrefMedlineGoogle Scholar2. Cannon CP, Pratley R, Dagogo-Jack S, et al; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425-35. [PMID: 32966714] doi:10.1056/NEJMoa2004967 CrossrefMedlineGoogle Scholar3. Pfeffer MA, Claggett B, Diaz R, et al; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247-57. [PMID: 26630143] doi:10.1056/NEJMoa1509225 CrossrefMedlineGoogle Scholar4. Holman RR, Bethel MA, Mentz RJ, et al; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228-39. [PMID: 28910237] doi:10.1056/NEJMoa1612917 CrossrefMedlineGoogle Scholar5. North EJ, Newman JD. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Curr Opin Cardiol. 2019;34:687-92. [PMID: 31436559] doi:10.1097/HCO.0000000000000673 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts* Drs. Everett and Kim contributed equally to this work and should be considered as co-senior authors.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-0893. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Elisabetta Patorno , Phyo T. Htoo , Robert J. Glynn , Sebastian Schneeweiss , Deborah J. Wexler , Ajinkya Pawar , Lily G. Bessette , Kristyn Chin , Brendan M. Everett , and Seoyoung C. Kim Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Elisabetta Patorno , Phyo T. Htoo , Robert J. Glynn , Sebastian Schneeweiss , Deborah J. Wexler , Ajinkya Pawar , Lily G. Bessette , Kristyn Chin , Brendan M. Everett , and Seoyoung C. Kim Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Mei Qiu Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Lurit Bepo , Anil N. Makam , and Oanh Kieu Nguyen Metrics January 2022Volume 175, Issue 1Page: W4KeywordsCardiovascular diseasesCohort studiesDrugsHeart failureHemorrhagic strokeHospital medicineIschemic strokeMortalityMyocardial infarctionPopulation statistics ePublished: 18 January 2022 Issue Published: January 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...